Table 1.
Renal Function, Age, and Body Weight Among Asians vs Non-Asians
| RE-LY4 |
ROCKET AF5 |
ARISTOTLE6 |
ENGAGE-AF7 |
|||||
|---|---|---|---|---|---|---|---|---|
| Asians (n = 2,782) | Non-Asians (n = 15,331) | Asians (n = 932) | Non-Asians (n = 13,322) | Asians (n = 1,993) | Non-Asians (n = 16,208) | Asians (n = 1,943) | Non-Asians (n = 19,162) | |
| CrCl <50 mL/min | 26.6% | 18.4% | 65 mL/min | 73 mL/min | 23.1% | 15.8% | 30% | 18.2% |
| Median age, y | 68 | 72 | 70 | 71 | 69 | 70 | 70 | 71 |
| Median weight, kg | 66 | 86 | 67 | 83 | 67 | 84 | 67 | 86 |
| Reduced dose | NAa | NAa | NR | NR | 4.77% | 4.34% | 46.9% | 23.2% |
ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; CrCl = creatinine clearance; ENGAGE-AF = Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation; NA = not available; NR = not reported; RE-LY = Randomized Evaluation of Long Term Anticoagulant Therapy; ROCKET AF = Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation.
a
There were no dose reduction criteria in the RE-LY trial.8